Myocardial protection by pioglitazone, atorvastatin, and their combination: Mechanisms and possible interactions

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 3, 2006, Pages

  Ye, Yumei ^a   Lin, Yu ^a   Atar, Shaul ^a   Huang, Ming He ^a   Perez Polo, Jose R ^b   Uretsky, Barry F ^a   Birnbaum, Yochai ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cyclooxygenase 2; Cytosolic phospholipase A2; Infarct size; Nitric oxide synthase; Phosphatase and tensin homologue deleted on chromosome 10, anti Src homology 2 containing inositol phosphatase 2; Protein kinase Akt; Statins; Thiazolidinediones

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ATORVASTATIN; CYCLOOXYGENASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; PIOGLITAZONE; PROSTAGLANDIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE III; ONCOGENE PROTEIN V-AKT; PHOSPHOLIPASES A; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; PYRAZOLES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; THIAZOLIDINEDIONES;

EID: 33748368084     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00096.2006     Document Type: Article

References (67)

1. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, and Birnbaum Y. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290: H1960-H1968, 2006.
2. Atkins KB, Northcott CA, Watts SW, and Brosius FC. Effects of PPAR-γ ligands on vascular smooth muscle marker expression in hypertensive and normal arteries. Am J Physiol Heart Circ Physiol 288: H235-H243, 2005.
3. Barthel A, Kruger KD, Roth RA, and Joost HG. Concentration-dependent stimulatory and inhibitory effect of troglitazone on insulin-induced fatty acid synthase expression and protein kinase B activity in 3T3-L1 adipocytes. Naunyn Schmiedebergs Arch Pharmacol 365: 290-295, 2002.
4. Bell RM and Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515, 2003.
5. Benkirane K, Amiri F, Diep QN, El Mabrouk M, and Schiffrin EL. PPAR-γ inhibits angiotensin II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290: H390-H397, 2006.
6. Birnbaum Y, Ashitkov T, Uretsky BF, Ballinger S, and Motamedi M. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther 17: 25-30, 2003.
7. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, and Uretsky BF. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 65: 345-355, 2005.
8. Bishop-Bailey D and Warner TD. PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J 17: 1925-1927, 2003.
9. Blume C, Sabuda-Widemann D, Pfeilschifter J, Plum J, Schror K, Grabensee B, and Beck KF. Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide. Eur J Pharmacol 485: 1-10, 2004.
10. Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, and Dawn B. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506-519, 2002.
11. Calnek DS, Mazzella L, Roser S, Roman J, and Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52-57, 2003.
12. Campbell IW. The clinical significance of PPAR gamma agonism. Curr Mol Med 5: 349-363, 2005.
13. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, and Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7: 48-52, 2001.
14. Chen WC, Lin MS, and Bai X. Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor gamma activation up-regulating PTEN and inhibiting PI3K activity. Chin Med J (Engl) 118: 1477-1481, 2005.
15. Cho DH, Choi YJ, Jo SA, and Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 279: 2499-2506, 2004.
16. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R, Artese L, Piattelli A, Chiarelli F, Cuccurullo F, and Mezzetti A. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107: 1479-1485, 2003.
17. Crosby MB, Svenson J, Gilkeson GS, and Nowling TK. A novel PPAR response element in the murine iNOS promoter. Mol Immunol 42: 1303-1310, 2005.
18. Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, and Gilkeson GS. Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J Pharmacol Exp Ther 312: 69-76, 2005.
19. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, and Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483: 79-93, 2004.
20. Degraeve F, Bolla M, Blaie S, Creminon C, Quere I, Boquet P, Levy-Toledano S, Bertoglio J, and Habib A. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 276: 46849-46855, 2001.
21. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, and Taton J. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROoactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 366: 1279-1289, 2005.
22. Efthymiou CA, Mocanu MM, and Yellon DM. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45: 247-252, 2005.
23. Farrow B and Evers BM. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 301: 50-53, 2003.
24. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F, Graf K, Law RE, Fleck E, and Grafe M. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293: 1431-1437, 2002.
25. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, and Jacober SJ. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 28: 1547-1554, 2005.
26. 1-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Circ Physiol 289: H2251-H2257, 2005.
27. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, and Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48: 96-104, 2005.
28. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Diaz C, Hernandez G, and Egido J. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 160: 49-58, 2002.
29. Hong G, Davis B, Khatoon N, Baker SF, and Brown J. PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun 303: 782-787, 2003.
30. Hori H, Sasaoka T, Ishihara H, Wada T, Murakami S, Ishiki M, and Kobayashi M. Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 51: 2387-2394, 2002.
31. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, and Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 288: C899-C905, 2005.
32. 12,14-prostaglandin J2 and thiazolidinediones transactivate epidermal growth factor and platelet-derived growth factor receptors in vascular smooth muscle cells. Biochem Biophys Res Commun 323: 402-408, 2004.
33. Inoue H, Tanabe T, and Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 275: 28028-28032, 2000.
34. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, and Katayama S. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67: 863-876, 2000.
35. Ito H, Nakano A, Kinoshita M, and Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83: 1715-1721, 2003.
36. Jones S, Gibson M, Rimmer D, Gibson T, Sharp B, and Lefer D. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40: 1172-1178, 2002.
37. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
38. Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, Kim JS, Lee MK, and Lee YC. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J 19: 1033-1035, 2005.
39. Levine L. Stimulated release of arachidonic acid by agonists of the peroxisome proliferator-activated receptor and retinoic acid receptors. Prostaglandins Leukot Essent Fatty Acids 65: 229-232, 2001.
40. Mendez M and LaPointe MC. PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 42: 844-850, 2003.
41. Mensah K, Mocanu MM, and Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45: 1287-1291, 2005.
42. Meyer MM, Levin K, Grimmsmann T, Perwitz N, Eirich A, Beck-Nielsen H, and Klein HH. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of Type 2 diabetes. Diabetes 51: 2691-2697, 2002.
43. Nissen SE, Wolski K, and Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA, 2005.
44. O'Neill BT and Abel ED. Akt1 in the cardiovascular system: friend or foe? J Clin Invest 115: 2059-2064, 2005.
45. Patel KM, Wright KL, Whittaker P, Chakravarty P, Watson ML, and Ward SG. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPARγ agonists: evidence for disparate functional effects which are independent of NF-κB and PPARγ. Cell Signal 17: 1098-1110, 2005.
46. Patel L, Pass I, Coxon P, Downes CP, Smith SA, and Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11: 764-768, 2001.
47. Pfutzner A, Hohberg C, Lubben G, Pahler S, Pfutzner AH, Kann P, and Forst T. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 37: 510-515, 2005.
48. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Uretsky BF, and Birnbaum Y. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 20: 27-36, 2006.
49. Ryan MJ, Didion SP, Mathur S, Faraci FM, and Sigmund CD. PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43: 661-666, 2004.
50. Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, Shinozaki Y, Ogai A, Fujita M, Hirata A, Kim J, Asano Y, Mori H, Tomoike H, Kitamura S, Hori M, and Kitakaze M. Optimal windows of statin use for immediate infarct limitation: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110: 2143-2149, 2004.
51. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM III, Trocha SD, Huang PL, Smith MB, Lefer AM, and Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103: 2598-2603, 2001.
52. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, and Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197-10202, 2000.
53. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, and Bolli R. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90: 602-608, 2002.
54. Singh N, Webb R, Adams R, Evans SA, Al-Mosawi A, Evans M, Roberts AW, and Thomas AW. The PPAR-gamma activator, rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium. Biochem Biophys Res Commun 333: 455-462, 2005.
55. Sly LM, Rauh MJ, Kalesnikoff J, Buchse T, and Krystal G. SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol 31: 1170-1181, 2003.
56. Starkopf J, Andreasen TV, Bugge E, and Ytrehus K. Lipid peroxidation, arachidonic acid and products of the lipoxygenase pathway in ischaemic preconditioning of rat heart. Cardiovasc Res 37: 66-75, 1998.
57. + channels. Coron Artery Dis 15: 53-58, 2004.
58. 3-receptors reduces myocardial infarct size. A novel insight into the cardioprotective effects of prostaglandins. Pharmacol Ther 87: 61-67, 2000.
59. Tsukamoto H, Hishinuma T, Suzuki N, Tayama R, Hiratsuka M, Yoshihisa T, Mizugaki M, and Goto J. Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. Prostaglandins Other Lipid Mediat 73: 191-213, 2004.
60. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, and Thiemermann C. Ligands of the peroxisome proliferator- activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J 16: 1027-1040, 2002.
61. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, Klein HH, Dominiak P, and Richardt G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-355, 2004.
62. Wood I. How can anti-diabetics suppress tumours? Trends Pharmacol Sci 22: 399, 2001.
63. Wynne AM, Mocanu MM, and Yellon DM. Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol 46: 817-822, 2005.
64. 2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104: 2210-2215, 2001.
65. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, and Jucker BM. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury. Diabetes 54: 554-562, 2005.
66. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, and Ohlstein EH. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104: 2588-2594, 2001.
67. 1 receptors: evidence from gene-knockout mice. Circulation 102: 902-907, 2000.